

PREVENT. PROTECT. IMPROVE.

We are Dedicated to Transforming the
Cardio-Renal Disease Treatment Paradigm

Our Vision


We are a clinical-stage biotech company dedicated to transforming outcomes in cardiothoracic surgical patients. **Renibus' first-in-class lead program, RBT-1** (stannic protoporphin/iron sucrose), is a potent inducer of anti-inflammatory, antioxidant and iron-scavenging pathways. RBT-1 has completed Phase 2 development and will soon enter a Phase 3 registration study for its lead indication to reduce the risk of postoperative complications and improve patient outcomes following cardiothoracic surgery.

Quick Facts:

Founded in 2016
and Headquartered
in Southlake, TX

Robust pipeline of programs to prevent
disease progression, improve outcomes
and protect against organ damage in
cardiorenal diseases.

Pipeline comprised of:
1 Phase 3 ready lead program
2 early clinical stage programs &
1 preclinical stage program



Leadership Team

Frank Stonebanks, *Co-Chief Executive Officer*

D. Jeff Keyser, RPh, JD, PhD, *Co-Chief Executive Officer*

Bhupinder Singh, MD, *Chief Medical Officer*

Jamie A. Donadio, *Chief Financial Officer*

Asha Ramdas, *SVP, Program Management, Technical
Operations & Manufacturing*

Board of Directors

Henrik Rasmussen, MD, PhD, *Chairman*









Frank Stonebanks, *Co-CEO & Director*

D. Jeff Keyser, RPh, JD, PhD, *Co-CEO, Secretary & Director*

Bhupinder Singh, MD, *Director*

Carlos Guillem, MBA, PhD, *Director*

We have developed a robust portfolio of products that act by activating multiple cytoprotective pathways.

Program	Indication/Condition	Pre-clinical	Phase 1	Phase2	Phase 3	Rights
RBT-1 Stannic protoporphin/iron sucrose	Reducing the risk of post op complications in cardiothoracic surgery					
RBT-3 Iron sucrose	Rapid resolution of anemia and limits damage associated with cisplatin induced nephrotoxicity					
RBT-9 Stannic protoporphin	TBD					
RBT-2 Antioxidant and anti-fibrotic	Slows progression of CKD					

Our patients are the core of what we do.

We'd like to express our appreciation for the patients who have previously participated or are currently enrolled in our clinical trials. Your contributions will help others as a result of the knowledge gained from your participation.



renibus
therapeutics

To learn more about Renibus visit renibus.com or scan the QR code to the right.

